Interestingly, PD-L1 upregulation is mostly restricted to HSCs in TP53-mutated AML, while T-cell immunity features low levels of PD-1 on CD8+ cytotoxic T-cells and an expansion of ICOShi/PD1− Tregs [78]. The gene discussed is TP53; the disease is acute myeloid leukemia.